|
|
Profile
|
Delegates :
Shigeru Kobayashi |
|
Incorporated :
February 8 , 2005 |
Paid in Capital :
5284 Million yen As of March 2017 |
Employees :
44 人 |
Address :
Sumitomo Fudosan Nishi-Shinjuku Bldg. No.6 3-12-1 Honmachi, Shibuya-ku TOKYO
〒151-0071
|
TEL/FAX :
+81-3-6383-3561 / +81-3-5302-1311 |
URL：
http://www.chiome.co.jp |
Attachment :
|
Mission/Background :
Chiome Bioscience is a biotech company established to commercialize the ADLib(R) system, a proprietary antibody discovery platform technology originally developed by RIKEN, for discovering therapeutic antibodies and providing drug discovery supports.
|
|
Technology & Business
|
Chiome utilizes various antibody discovery platform technologies, including its proprietary ADLib(R) system, to discover and develop therapeutic antibodies with a focus on targeting cancer or diseases with high unmet medical needs. The development of anticancer drugs (humanized or fully-human monoclonal antibodies) is conducted in house from research to preclinical stage, with data set aiming for out-licensing to or co-development with strategic partners. Selected programs may also be developed in house up to early clinical phase.
Chiome also provides drug discovery support to other companies by leveraging unique ADLib(R) system for antibody screening and accumulated know-hows of protein engineering.
Main corporate partnerships include Chugai Pharmaceutical (a member of the Roche group) and Mitsubishi Tanabe Pharma Corporation.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
ADLib(R) system
|
Service/Marketing
|
Technology for generating monoclonal antibodies
|
Building up collaborations and business partnerships.
|
LIV-1205 (humanized anti-DLK-1 monoclonal antibody)
|
Preclinical
|
First-in-class therapeutic drug candidate for cancers un-responsive to standard therapy.
|
Aiming for out-licensing; CMC and GLP activities initiated.
|
LIV-2008 (humanized anti-TROP-2 monoclonal antibody)
|
Preclinical
|
Best-in-class therapeutic candidate targeting breast cancer and lung cancer etc.
|
Aiming for out-licensing.
|
BMAA (humanized anti-semaphorin 3A monoclonal antibody)
|
Preclinical
|
Discovered through the ADLib(R) system.
|
Aiming for out-licensing.
|
|
|
|
|
|
Highlights
|
Concluded an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) and Tanabe Research Laboratories U. S. A., Inc. (TRL, a wholly-owned subsidiary of MTPC) in Dec. 2016.
Invested in Trans Chromosomics, Inc. in Jan. 2017.
|
|
Alliance strategy
|
Chiome aims to develop therapeutic antibodies targeting diseases with high unmet medical needs by leveraging several antibody discovery platforms, including the ADLib® system. All pipelines currently under evaluation are of preclinical stage with the goal of out-licensing at either preclinical or early clinical phase. In addition to in-house programs, Chiome also seeks for the opportunity of collaborations or antibody discovery projects with industries and research institutes.
|
|
|